TONIX PHARMACEUTICALS HOLDING CORP. Repayments of Long-Term Debt
TONIX PHARMACEUTICALS HOLDING CORP. (TNXP) reported Repayments of Long-Term Debt of $9.65 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfLongTermDebt · last filed 2026-08-10
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for the quarter ending 2025-03-31 was $9.65M, a 4006.38% increase year-over-year.
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for fiscal 2025 was $9.65M, a 310.64% increase from fiscal 2024.
- TONIX PHARMACEUTICALS HOLDING CORP. repayments of long-term debt for fiscal 2024 was $2.35M.
| Period end | Repayments of Long-term Debt 3 month | Repayments of Long-term Debt 6 month | Repayments of Long-term Debt 9 month | Repayments of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-10 | $9.65M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-10 | $9.65M 10-Q · filed 2025-11-10 | $10.36M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $9.65M 10-Q · filed 2026-08-10 | $10.36M derived: sum of 3 quarters · filed 2026-08-10 | $11.06M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $9.65M 10-Q · filed 2026-05-11 | $10.36M derived: sum of 2 quarters · filed 2026-05-11 | $11.06M derived: sum of 3 quarters · filed 2026-05-11 | $11.77M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $705.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.41M derived: sum of 2 quarters · filed 2026-03-12 | $2.12M derived: sum of 3 quarters · filed 2026-03-12 | $2.35M 10-K · filed 2026-03-12 |
| 2024-09-30 | $705.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $1.41M derived: sum of 2 quarters · filed 2025-11-10 | $1.65M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $705.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $940.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $235.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |